Farletuzumab: Phase I data

A single-arm, open-label Phase I trial in 15 patients with platinum-sensitive epithelial ovarian cancer showed that once-weekly 2.5 mg/kg farletuzumab plus carboplatin and pegylated liposomal doxorubicin every 4 weeks for 6 cycles produced 1 complete response, 10 partial responses and 4 cases of stable disease. Median PFS was 11 months. Adverse events deemed to be possibly related to farletuzumab or chemotherapy included 2 cases of small bowel obstruction in the same patient and 1 case of fatigue. Data will be presented at the American Society of Clinical Oncology meeting in Chicago in June. ...